Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr;75(Suppl 1):287-294.
doi: 10.1007/s13224-024-01974-w. Epub 2024 Jun 12.

A Cohort Study of Pregnancy and Fetal Complications Among Patients with Rheumatologic Disorders

Affiliations

A Cohort Study of Pregnancy and Fetal Complications Among Patients with Rheumatologic Disorders

Shadan Tafreshian et al. J Obstet Gynaecol India. 2025 Apr.

Abstract

Objective: We aim to investigate the maternal and fetal complications among women with rheumatic diseases (RDs) and evaluate the risk factors for adverse pregnancy outcomes.

Methods: In this cohort study, 241 women (comprising 401 pregnancies) who were diagnosed with RDs and sought treatment between 2016 and 2021 were evaluated and followed up for a duration of two years. Clinical backgrounds, pregnancy history, medication usage, immunological characteristics, and pregnancy outcomes were analyzed. Risk assessment for adverse outcomes in RDs was performed using binary logistic regression.

Results: The study revealed a 38.2% miscarriage rate and 56.9% live birth rate among 401 pregnancies. Maternal adverse events included gestational hypertension (4.7%), gestational diabetes mellitus (2.7%), and (pre)eclampsia (1.7%). Fetal adverse outcomes consisted of miscarriages in 153 (38.2%), low birth weight in 45 (11.2%), preterm labor in 20 (5%), and fetal heart block in eight (2%). Risk factors associated with adverse fetal outcomes were systemic lupus erythematosus (SLE) (OR 8.24, 95% CI 1.65-41.15), vasculitis (OR 8.06, 95% CI 2.7-24.02), SLE/Sjögren's syndrome (SS) overlap (OR 4.05, 95% CI 1.8-9.11), and history of hypothyroidism (OR 2.81, 95% CI 1.52-5.2).

Conclusion: RDs exerted a negative impact on pregnancy outcomes, resulting in complications for both the mother and the fetus. Our study emphasizes the significance of effectively managing RDs during pregnancy, with particular emphasis on SLE, vasculitis, and the overlap of SS with SLE. To improve pregnancy outcomes, a multidisciplinary approach, early identification of high-risk patients, and the implementation of individualized treatment plans are recommended.

Keywords: Maternal; Neonatal; Pregnancy; Pregnancy outcome; Rheumatic disease; Rheumatoid arthritis; Systemic lupus erythematous.

PubMed Disclaimer

Conflict of interest statement

Conflict of InterestThe authors declare that they have no competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Similar articles

References

    1. Sugawara E, Kato M, Fujieda Y, Oku K, Bohgaki T, Yasuda S, et al. Pregnancy outcomes in women with rheumatic diseases: a real-world observational study in Japan. Lupus. 2019;28(12):1407–16. - PubMed
    1. Carvalheiras G, Faria R, Braga J, Vasconcelos C. Fetal outcome in autoimmune diseases. Autoimmun Rev. 2012;11(6–7):A520–30. - PubMed
    1. Sieiro Santos C, Moriano Morales C, Álvarez Castro C, González Fernández I, Díez ÁE. Factors associated with adverse pregnancy outcomes in patients with systemic lupus erythematosus. Musculoskeletal Care. 2022;20(4):917–25. - PubMed
    1. Spinillo A, Beneventi F, Ramoni V, Caporali R, Locatelli E, Simonetta M, et al. Prevalence and significance of previously undiagnosed rheumatic diseases in pregnancy. Ann Rheum Dis. 2012;71(6):918–23. - PubMed
    1. Bermas BL, Tassinari M, Clowse M, Chakravarty E. The new FDA labeling rule: impact on prescribing rheumatological medications during pregnancy. Rheumatology. 2018;57(suppl_5):v2–8. - PMC - PubMed